Εvaluation of triple biochemical test in prenatal screening for chromosomal abnormalities

Rizos D, Hassiakos D, Botsis D, Kassanos D, Kolovos B, Sarandakou A, Salamalekis E, Creatsas G

2nd Department of Obstetrics and Gynecology, Medical School, University of Athens, Hormone laboratory, Aretaieio hospital, Athens, Greece

Correspondence: Rizos Demetrios, 76 Vasilissis Sofias Avenue, GR-11528 Athens, Greece. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

 


 

Abstract

The aim of this study was to present the results of prenatal screening for chromosomal abnormalities with the triple biochemical test in the second department of obstetrics and gynecology at Aretaieio hospital during an eight years period. In our hospital, the triple biochemical test (chorionic gonadotropin, alpha-fetoprotein and unconjugated estriol) in the second trimester of pregnancy was inititated in 1994. Until September 2002, a total of 4,231 triple tests were performed. We analyzed data from 1,913 cases of singleton pregnancies. We found a false positive rate of 4.94%. Eight embryos had chromosomal abnormalities, and 6 of them gave positive triple test (detection rate: 75%). The detection rate for fetuses with chromosomal abnormalities in our center is very satisfactory and comparable with that reported in the literature. Triple biochemical test remains a reliable choice for the prenatal screening for chromosomal abnormalities.

 

Key words: prenatal screening; chromosomal abnormalities; Down’s syndrome; triple test; chorionic gonadotropin; alphafetoprotein; unconjugated estriol